Issue link: http://viewer.e-digitaledition.com/i/884976
" I think there will be a day that we'll all be using liquid biopsies more routinely, even perhaps in certain cases, instead of tissue biopsies — not necessarily to diagnose cancer, but to perform molecular diagnostics in patients who are already known to have cancer ... . No. 1, it's going to be safer and cheaper if tissue biopsy can be avoided, and No. 2, it's going to be much more reliable than it is today. But I'm not particularly ready at this point to just test all patients with liquid biopsies because I'm not convinced it correlates completely with tissue biopsies." SIBEL BLAU, MD, HEMATOLOGIST/ONCOLOGIST AND MEDICAL DIRECTOR AT RAINIER DIVISION OF NORTHWEST MEDICAL SPECIALTIES non i nv a sive n at u re of blood-ba sed liquid cancer biopsies, however, there a re cases in which liquid biopsy may o‡ er an advantage. " S o m e t u m o r s a r e l o c a t e d i n places t hat a re d i f f icu lt , da ngerous o r r i s k y t o b i o p s y [v i a n e e d l e o r s u r ger y] ," s ay s S ho s h a n n a h R ot h , PhD, Ma nager of Hea lth Technolog y A ssessment Information Ser vices at the Pennsylvania-based ECRI Institute. "Also, in patients with metastatic cancer, it's somewhat impractica l to biopsy a ll of the di‡ erent tumor seeds around the body. ... Another advantage is that since these tests are typica lly noninvasive — you're looking at a blood or maybe a urine sample — it can reduce patient anxiety because they don't have to undergo a painful test." S o fa r, one l iqu id biops y t es t h a s received FDA approval. The blood-based test is indicated for patients with non- small cell lung cancer and is designed to detect epidermal growth factor receptor gene mutations in tumors. "Lung ca ncer is where we have the mos t t a rget ed t herapy opt ion s , but getting enough tissue to run molecular a s s ay s h a s b e c ome a n i s s ue ," s ay s Young Kwa ng Chae, MD, MPH, MBA , A s s i s t a n t P r o f e s s o r o f M e d i c i n e , Division of Hematolog y/Oncolog y at Nor thwestern Universit y 's Feinberg School of Medicine. O n e o f t h e lu n g c a n c e r -r e l a t e d cha l lenges physicia ns face is tissue ne c r o s i s , wh ic h c a n h a mp er t hei r ability to collect su¢ cient tumor cells for molecular ana lysis. "That's where the blood assay becomes much more useful," Dr. Chae says. "And sometimes, [in cases of ] prog ression of d i s ea s e where we're lo ok i n g for e m e r g e n c e o f m u t a t i o n s , i t 's t h i s noninvasive approach that might save a patient from having an invasive biopsy." T h a t s a i d , l i q u i d c a n c e r bi o p s y has limitations. " We h aven't y e t de t er m i ne d t he best time to per form a liquid biopsy test," Roth says. " We know the DNA circulating in these liquids might change over the course of the disease, and we don't know how that infl uences the test results at this time. Related to that, some early studies have already reported some confl icting results between traditiona l tissue biopsy genetic ana lysis and the liquid biopsy genetic a na lysis, so we need to learn more about that and how that might impact patients." COMPLEMENT OR COMPETITOR? Research funded by Guardant Health, the manufacturer of a liquid cancer biopsy test known as Guardant360, eva luated nearly 400 patients for whom both liquid cancer biopsy and tissue biopsy results were available. Overa ll accuracy of the liquid biopsy in comparison with tissue biopsy wa s 87 percent , according to the Nationa l Ca ncer Institute. Other studies in which researchers performed both liquid ca ncer biopsy a nd tissue biopsy in the sa me patients, however, found lower levels of concordance. Sibel Blau, MD, hematologist/oncologist and Medica l Director at Rainier Division of Northwest Medical Specialties, based in Washing ton state, believes divergence is to be expected. " Th is is not u ncom mon when you actua lly look at different companies and different commercial labs," says Dr. Blau, whose JA MA Oncology-published study fou nd g reat d i screpa ncies bet ween liquid ca ncer a nd tissue biopsy results. "... [E]ven with tissue, [ you may have] d i s c r e p a n c i e s w i t h i n t h e r e s u l t s because the way that [ labs] do testing may be different. The liquid biopsy looks at ver y different aspects of testing. It 's looking at the DNA that has been shed into the bloodstrea m." " We need to educate ourselves that t hese t wo a re rea l ly dif ferent tests," Dr. Chae adds. "In the future, they will most likely complement each other." ■ M D N E W S .C O M /// M D N E W S M I D P E N N ■ 2 017 0 5

